Teva Pharmaceutical Industries Ltd. $TEVA Shares Purchased by Dorsey Wright & Associates

Dorsey Wright & Associates increased its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 43.8% in the first quarter, Holdings Channel reports. The institutional investor owned 75,563 shares of the company’s stock after acquiring an additional 23,030 shares during the quarter. Dorsey Wright & Associates’ holdings in Teva Pharmaceutical Industries were worth $2,276,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in TEVA. Harel Insurance Investments & Financial Services Ltd. increased its position in shares of Teva Pharmaceutical Industries by 2.2% in the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 45,956,714 shares of the company’s stock worth $1,384,216,000 after purchasing an additional 1,004,941 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd grew its stake in Teva Pharmaceutical Industries by 18.8% in the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 37,404,106 shares of the company’s stock worth $1,171,378,000 after purchasing an additional 5,917,423 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. grew its stake in Teva Pharmaceutical Industries by 14.8% in the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 37,402,212 shares of the company’s stock worth $1,167,323,000 after purchasing an additional 4,820,000 shares in the last quarter. Norges Bank bought a new stake in Teva Pharmaceutical Industries in the fourth quarter valued at about $1,098,060,000. Finally, Rubric Capital Management LP increased its holdings in Teva Pharmaceutical Industries by 1.8% in the second quarter. Rubric Capital Management LP now owns 26,000,000 shares of the company’s stock valued at $435,760,000 after buying an additional 450,000 shares during the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, insider Mark Sabag sold 144,180 shares of the company’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $34.99, for a total value of $5,044,858.20. Following the transaction, the insider owned 80,760 shares of the company’s stock, valued at approximately $2,825,792.40. This represents a 64.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Amir Weiss sold 10,679 shares of the business’s stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $36.00, for a total value of $384,444.00. Following the sale, the chief accounting officer directly owned 20,016 shares in the company, valued at $720,576. This trade represents a 34.79% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 465,931 shares of company stock worth $16,332,989. Company insiders own 0.54% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on TEVA. UBS Group boosted their price target on Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, April 30th. Barclays lifted their price objective on shares of Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. Bank of America boosted their target price on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, April 9th. Piper Sandler reissued an “overweight” rating and set a $42.00 target price (up from $41.00) on shares of Teva Pharmaceutical Industries in a report on Thursday, April 30th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Monday, April 20th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Teva Pharmaceutical Industries currently has an average rating of “Moderate Buy” and a consensus target price of $41.78.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA stock opened at $32.00 on Friday. Teva Pharmaceutical Industries Ltd. has a 12-month low of $14.99 and a 12-month high of $37.35. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.01 and a quick ratio of 0.78. The firm has a market capitalization of $36.79 billion, a price-to-earnings ratio of 24.06, a price-to-earnings-growth ratio of 3.40 and a beta of 0.86. The business has a 50 day simple moving average of $33.76 and a 200 day simple moving average of $32.69.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Tuesday, March 31st. The company reported $0.53 EPS for the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. The firm had revenue of $3.98 billion for the quarter. On average, equities research analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 1.99 EPS for the current year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.